EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia

Erhan Aptullahoglu iD, Jonathan P Wallis, Helen Marr, Scott Marshall, Nick Bown, Elaine Willmore iD, John Lunec iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241411335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Erhan Aptullahoglu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty, Newcastle University Cancer Centre, Newcastle upon Tyne NE2 4AD, UK. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Proto-Oncogene Proteins c-mdm2, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JGW Patterson Foundation, Newcastle Healthcare Charity, Bloodwise.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic lymphocytic leukemia (CLL) is a genetically and clinically heterogeneous malignancy affecting older individuals. There are a number of current treatment options for CLL, including monoclonal antibodies, targeted drugs, chemotherapy, and different combinations of these. However, for those patients who are intrinsically treatment resistant, or relapse following initial responses, novel targeted therapies are still needed. Targeting the mouse double-minute-2 human homolog (MDM2), a primary negative regulator of p53, is an appealing therapeutic strategy for non-genotoxic reactivation of p53, since the TP53 gene is in its wild-type state at diagnosis in approximately 90% of patients. Mutated SF3B1 and TP53 are both associated with more aggressive disease, resistance to therapies and poorer overall survival for CLL. In this study, we performed a screen for SF3B1 and TP53 mutations and tested RG7388 (idasanutlin), a second-generation MDM2 inhibitor, in a cohort of CLL primary patient samples. SF3B1 mutations were detected in 24 of 195 cases (12.3%) and found associated with poor overall survival (hazard ratio [HR] 2.12, p = 0.032) and high CD38 expression (median CD38 (%) 32 vs. 5; p = 0.0087). The novel striking finding of this study was an independent link between SF3B1 mutational status and poor response to RG7388. Overall, SF3B1 mutations in CLL patient samples were associated with resistance to treatment with RG7388 ex vivo, and patients with the wild type for both SF3B1 and TP53 are more likely to benefit from treatment with MDM2 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellProto-Oncogene Proteins c-mdm2Drug Resistance, NeoplasmHumansMutationPhosphoproteinsRNA Splicing FactorsTumor Suppressor Protein p53Pyrrolidinespara-Aminobenzoates

Stichwörter der Autor:innen

MDM2-p53 antagonistsRG7388 (idasanutlin)SF3B1chronic lymphocytic leukemia (CLL)splicing factor

Substanzen

PhosphoproteinsProto-Oncogene Proteins c-mdm2RNA Splicing FactorsTumor Suppressor Protein p53MDM2 protein, humanRG7388Pyrrolidinespara-AminobenzoatesSF3B1 protein, human

Autor:innen und Institutionen

  • Medical Faculty, Newcastle University Cancer Centre, Newcastle upon Tyne NE2 4AD, UK.
  • Department of Haematology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK.
  • Department of Haematology, City Hospitals Sunderland NHS Trust, Sunderland SR4 7TP, UK.
  • Northern Genetics Service, Institute of Genetic Medicine, Newcastle upon Tyne NE1 4EP, UK.

ORCID-Profile: Erhan Aptullahoglu, Elaine Willmore, John Lunec

Förderung

  • JGW Patterson Foundation
  • Newcastle Healthcare Charity
  • Bloodwise
  • Cancer Research UK
  • Blood Cancer UK
  • JGW Paterson Foundation
  • Turkish Ministry of National Education

Zitieren

APA

Aptullahoglu, E., Wallis, J. P., Marr, H., Marshall, S., Bown, N., Willmore, E., & Lunec, J. (2023). SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241411335

Vancouver

Aptullahoglu E, Wallis JP, Marr H, Marshall S, Bown N, Willmore E, et al. SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241411335

BibTeX
@article{Aptullahoglu2023,
  author = {Aptullahoglu, Erhan and Wallis, Jonathan P and Marr, Helen and Marshall, Scott and Bown, Nick and Willmore, Elaine and Lunec, John},
  title = {SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241411335}
}
Kostenlos starten →